Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. Patient Characteristics
3.2. Drop-Out Analyses
3.3. Descriptive Results
3.4. Clinical Pairwise Comparisons
3.5. Regression Analyses
4. Discussion
Limitations/Strengths
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Cornish, D.; Holterhues, C.; van de Poll-Franse, L.V.; Coebergh, J.W.; Nijsten, T. A systematic review of health-related quality of life in cutaneous melanoma. Ann. Oncol. 2009, 20, vi51–vi58. [Google Scholar] [CrossRef] [PubMed]
- Beutel, M.E.; Fischbeck, S.; Binder, H.; Blettner, M.; Brähler, E.; Emrich, K.; Friedrich-Mai, P.; Imruck, B.H.; Weyer, V.; Zeissig, S.R. Depression, Anxiety and Quality of Life in Long-Term Survivors of Malignant Melanoma: A Register-Based Cohort Study. PLoS ONE 2015, 10, e0116440. [Google Scholar] [CrossRef] [PubMed]
- Al-Shakhli, H.; Harcourt, D.; Kenealy, J. Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinic. J. Plast. Reconstr. Aesthetic Surg. 2006, 59, 479–486. [Google Scholar] [CrossRef] [PubMed]
- Robinson, D.W.; Cormier, J.N.; Zhao, N.; Uhlar, C.M.; Revicki, D.A.; Cella, D. Health-related quality of life among patients with metastatic melanoma. Melanoma Res. 2012, 22, 54–62. [Google Scholar] [CrossRef] [PubMed]
- Cormier, J.N.; Ross, M.I.; Gershenwald, J.E.; Lee, J.E.; Mansfield, P.F.; Camacho, L.H.; Kim, K.; Ma, K.W.; Cella, D.; Palmer, J.L. Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy-Melanoma questionnaire. Cancer 2008, 112, 2249–2257. [Google Scholar] [CrossRef] [PubMed]
- Ekenberg, M.; Wesslau, H.; Bagge, R.O.; Engström, M. Patient experiences with isolated limb perfusion for malignant melanoma – A qualitative study. Eur. J. Oncol. Nurs. 2019, 43, 101672. [Google Scholar] [CrossRef]
- Pawlik, T.M.; Ross, M.I.; Johnson, M.M.; Schacherer, C.W.; McClain, D.M.; Mansfield, P.F.; Lee, J.E.; Cormier, J.N.; Gershenwald, J.E. Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy. Ann. Surg. Oncol. 2005, 12, 587–596. [Google Scholar] [CrossRef] [PubMed]
- Read, R.L.; Haydu, L.; Saw, R.P.M.; Quinn, M.J.; Shannon, K.; Spillane, A.J.; Stretch, J.R.; Scolyer, R.A.; Thompson, J.F. In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Ann. Surg. Oncol. 2014, 22, 475–481. [Google Scholar] [CrossRef]
- Gershenwald, J.E.; Scolyer, R.A.; Hess, K.R.; Sondak, V.K.; Long, G.V.; Ross, M.I.; Lazar, A.J.; Faries, M.B.; Kirkwood, J.M.; McArthur, G.A.; et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017, 67, 472–492. [Google Scholar] [CrossRef] [Green Version]
- Barreiro-Capurro, A.; Andrés-Lencina, J.J.; Podlipnik, S.; Carrera, C.; Requena, C.; Manrique-Silva, E.; Quaglino, P.; Tonella, L.; Jaka, A.; Richarz, N.; et al. Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study. Eur. J. Cancer 2021, 145, 29–37. [Google Scholar] [CrossRef]
- Testori, A.; Ribero, S.; Bataille, V. Diagnosis and treatment of in-transit melanoma metastases. Eur. J. Surg. Oncol. (EJSO) 2017, 43, 544–560. [Google Scholar] [CrossRef] [PubMed]
- Speicher, P.J.; Meriwether, C.H.; Tyler, D.S. Regional Therapies for In-transit Disease. Surg. Oncol. Clin. N. Am. 2015, 24, 309–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holmberg, C.-J.; Ny, L.; Hieken, T.J.; Block, M.S.; Carr, M.J.; Sondak, V.K.; Örtenwall, C.; Katsarelias, D.; Dimitriou, F.; Menzies, A.M.; et al. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. Eur. J. Cancer 2022, 169, 210–222. [Google Scholar] [CrossRef] [PubMed]
- Olofsson, R.; Mattsson, J.; Lindnér, P. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. Int. J. Hyperth. 2013, 29, 551–557. [Google Scholar] [CrossRef]
- Kenyon-Smith, T.J.; Kroon, H.M.; Miura, J.T.; Teras, J.; Beasley, G.M.; Mullen, D.; Farrow, N.E.; Mosca, P.J.; Lowe, M.C.; Farley, C.R.; et al. Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. Eur. J. Surg. Oncol. (EJSO) 2020, 46, 2140–2146. [Google Scholar] [CrossRef]
- Dossett, L.; Ben-Shabat, I.; Bagge, R.O.; Zager, J.S. Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Ann. Surg. Oncol. 2016, 23, 2330–2335. [Google Scholar] [CrossRef]
- Thompson, J.; Agarwala, S.S.; Smithers, B.M.; Ross, M.I.; Scoggins, C.R.; Coventry, B.J.; Neuhaus, S.J.; Minor, D.R.; Ms, J.M.S.; Wachter, E.A. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Ann. Surg. Oncol. 2014, 22, 2135–2142. [Google Scholar] [CrossRef] [Green Version]
- Read, T.A.; Smith, A.; Thomas, J.; David, M.; Foote, M.; Wagels, M.; Barbour, A.; Smithers, B.M. Intralesional PV-10 for the treatment of in-transit melanoma metastases—Results of a prospective, non-randomized, single center study. J. Surg. Oncol. 2018, 117, 579–587. [Google Scholar] [CrossRef] [Green Version]
- Andtbacka, R.H.; Kaufman, H.L.; Collichio, F.; Amatruda, T.; Senzer, N.; Chesney, J.; Delman, K.A.; Spitler, L.E.; Puzanov, I.; Agarwala, S.S.; et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J. Clin. Oncol. 2015, 33, 2780–2788. [Google Scholar] [CrossRef]
- Carr, M.J.; Sun, J.; DePalo, D.; Rothermel, L.D.; Song, Y.; Straker, R.J.; Baecher, K.; Louie, R.J.; Stahlie, E.H.A.; Wright, G.P.; et al. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Ann. Surg. Oncol. 2021, 29, 791–801. [Google Scholar] [CrossRef]
- Bagge, A.-S.L.; Wesslau, H.; Cizek, R.; Holmberg, C.J.; Moncrieff, M.; Katsarelias, D.; Carlander, A.; Bagge, R.O. Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review. Eur. J. Surg. Oncol. (EJSO) 2021, 48, 312–319. [Google Scholar] [CrossRef] [PubMed]
- Bs, B.S.J.; Speicher, P.J.; Mb, S.T.; Mosca, P.J.; Abernethy, A.P.; Tyler, D.S. Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity. Ann. Surg. Oncol. 2014, 22, 1694–1700. [Google Scholar] [CrossRef] [Green Version]
- Bagge, A.-S.L.; Ben-Shabat, I.; Belgrano, V. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion. Ann. Surg. Oncol. 2016, 23, 2062–2069. [Google Scholar] [CrossRef] [PubMed]
- Yeung, C.; Petrella, T.M.; Wright, F.C.; Abadir, W.; Hong, N.J.L. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: An inaugural Canadian series. Expert Rev. Clin. Immunol. 2017, 13, 383–388. [Google Scholar] [CrossRef] [PubMed]
- McClaine, R.J.; Giglia, J.S.; Ahmad, S.A.; McCoy, S.J.; Sussman, J.J. Quality of Life Outcomes after Isolated Limb Infusion. Ann. Surg. Oncol. 2012, 19, 1373–1378. [Google Scholar] [CrossRef]
- Lenn, L.C.; Oberle, C.T.; McKinnon, J.G. Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma. Plast. Surg. 2015, 23, 25–30. [Google Scholar] [CrossRef]
- Cella, D.F.; Tulsky, D.S. Quality of Life in Cancer: Definition, Purpose, and Method of Measurement. Cancer Investig. 1993, 11, 327–336. [Google Scholar] [CrossRef]
- Askew, R.L.; Xing, Y.; Palmer, J.L.; Cella, D.; Moye, L.A.; Cormier, J.N. Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire. Value Health 2009, 12, 1144–1150. [Google Scholar] [CrossRef] [Green Version]
- Schünemann, H.J.; Guyatt, G.H. Commentary--goodbye M(C)ID! Hello MID, where do you come from? Health Serv. Res. 2005, 40, 593–597. [Google Scholar] [CrossRef]
- Bharmal, M.; Nolte, S.; Henry-Szatkowski, M.; Hennessy, M.; Schlichting, M. Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma. Health Qual. Life Outcomes 2020, 18, 145. [Google Scholar] [CrossRef]
- Steel, J.L.; Eton, D.T.; Cella, D.; Olek, M.C.; Carr, B.I. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann. Oncol. 2006, 17, 304–312. [Google Scholar] [CrossRef] [PubMed]
- Cella, D.; Hahn, E.A.; Dineen, K. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual. Life Res. 2002, 11, 207–221. [Google Scholar] [CrossRef] [PubMed]
- Yost, K.J.; Eton, D. Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences. Eval. Health Prof. 2005, 28, 172–191. [Google Scholar] [CrossRef]
- Hayes, A.F.; Coutts, J.J. Use Omega Rather than Cronbach’s Alpha for Estimating Reliability. But…. Commun. Methods Meas. 2020, 14, 1–24. [Google Scholar] [CrossRef]
- Iacobucci, D.; Posavac, S.S.; Kardes, F.R.; Schneider, M.J.; Popovich, D.L. The median split: Robust, refined, and revived. J. Consum. Psychol. 2015, 25, 690–704. [Google Scholar] [CrossRef]
- Bagge, A.-S.L.; Carlander, A.; Fahlke, C.; Bagge, R.O. Health-related quality of life (FACT-GP) in Sweden. Health Qual. Life Outcomes 2020, 18, 172. [Google Scholar] [CrossRef]
- Naseri, N.; Taleghani, F. Social support in cancer patients referring to Sayed Al-Shohada Hospital. Iran. J. Nurs. Midwifery Res. 2012, 17, 279–283. [Google Scholar] [PubMed]
- Schwarz, R.; Hinz, A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur. J. Cancer 2001, 37, 1345–1351. [Google Scholar] [CrossRef]
- Holzner, B.; Kemmler, G.; Cella, D.; De Paoli, C.; Meraner, V.; Kopp, M.; Greil, R.; Fleischhacker, W.W.; Sperner-Unterweger, B. Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol. 2004, 43, 153–160. [Google Scholar] [CrossRef] [Green Version]
- Laghousi, D.; Jafari, E.; Nikbakht, H.; Nasiri, B.; Shamshirgaran, M.; Aminisani, N. Gender differences in health-related quality of life among patients with colorectal cancer. J. Gastrointest. Oncol. 2019, 10, 453–461. [Google Scholar] [CrossRef]
- Derogar, M.; Van Der Schaaf, M.; Lagergren, P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol. 2011, 51, 10–16. [Google Scholar] [CrossRef] [PubMed]
- Galdas, P.M.; Cheater, F.; Marshall, P. Men and health help-seeking behaviour: Literature review. J. Adv. Nurs. 2005, 49, 616–623. [Google Scholar] [CrossRef] [PubMed]
- Brucker, P.S.; Yost, K.; Cashy, J.; Webster, K.; Cella, D. General Population and Cancer Patient Norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval. Health Prof. 2005, 28, 192–211. [Google Scholar] [CrossRef] [PubMed]
- Molassiotis, A.; Brunton, L.; Hodgetts, J.; Green, A.; Beesley, V.; Mulatero, C.; Newton-Bishop, J.; Lorigan, P. Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. Ann. Oncol. 2014, 25, 2052–2058. [Google Scholar] [CrossRef] [PubMed]
Sex | |||
---|---|---|---|
Female (n) | Male (n) | ||
Age | ≤72 yrs | 22 | 27 |
>72 yrs | 23 | 23 | |
Lymph node metastases | No | 27 | 28 |
Yes Missing | 15 3 | 18 4 | |
Tumor localization | Leg | 41 | 42 |
Arm Missing | 4 0 | 8 0 | |
Numbers of tumors | <10 | 32 | 30 |
≥10 Missing | 13 0 | 19 1 | |
Tumor size | <20 mm | 33 | 29 |
≥20 mm Missing | 12 0 | 18 3 |
Scales | M | SD | ω |
---|---|---|---|
FACT-M | 140.1 | 20.4 | 0.91 |
FACT-G | 86.2 | 13.9 | 0.95 |
PWB | 24.4 | 3.8 | 0.81 |
SWB | 23.8 | 4.6 | 0.90 |
EWB | 18.1 | 4.5 | 0.83 |
FWB | 19.8 | 5.8 | 0.90 |
MS | 53.5 | 7.6 | 0.81 |
MSS | 23.6 | 6.7 | 0.87 |
PWB | SWB | EWB | FWB | MS | MSS | FACT-G | FACT-M | ||
---|---|---|---|---|---|---|---|---|---|
Sex | Female | 23.6 ± 4.39 * | 23.8 ± 4.47 | 17.2 ± 4.96 * | 19.1 ± 5.75 | 52.4 ± 8.32 | 22.4 ± 7.04 | 84.0 ± 15.07 | 135.6 ± 23.15 |
Male | 25.2 ± 3.12 | 23.8 ± 4.84 | 19.1 ± 3.83 | 20.5 ± 5.82 | 54.6 ± 6.75 | 24.5 ± 6.36 | 88.3 ± 12.40 | 144.0 ± 16.97 | |
Age | <72 | 24.3 ± 4.60 | 23.8 ± 4.94 | 17.7 ± 5.04 | 20.5 ± 6.77 | 52.5 ± 9.06 | 21.6 ± 7.36 ** | 86.3 ± 16.58 | 138.5 ± 24.61 |
>72 | 24.6 ± 2.82 | 23.7 ± 4.33 | 18.6 ± 3.79 | 19.1 ± 4.48 | 54.7 ± 5.45 | 25.9 ± 5.05 | 86.1 ± 9.98 | 142.0 ± 13.77 | |
Number of tumors | <10 | 24.9 ± 3.59 | 23.7 ± 4.88 | 19.1 ± 3.10 | 21.0 ± 5.18 | 55.1 ± 6.75 | 24.1 ± 5.81 | 88.5 ± 12.58 | 143.8 ± 17.77 |
≥10 | 23.6 ± 4.28 | 23.8 ± 4.24 | 16.3 ± 6.05 ** | 17.5 ± 6.34 ** | 50.6 ± 8.33 ** | 22.9 ± 7.93 | 81.7 ± 15.43 * | 132.3 ± 23.82 * | |
Tumor diameter | <20 mm | 25.1 ± 3.09 | 23.8 ± 4.80 | 18.1 ± 4.83 | 20.1 ± 5.94 | 54.3 ± 6.84 | 24.4 ± 6.14 | 87.2 ± 13.87 | 141.8 ± 19.92 |
≥20 mm | 23.5 ± 4.88 | 23.6 ± 4.53 | 18.8 ± 3.27 | 19.5 ± 5.55 | 52.7 ± 8.87 | 22.2 ± 7.11 | 85.2 ± 14.08 | 138.0 ± 21.26 | |
Tumor localization | Leg | 24.3 ± 4.02 | 23.8 ± 4.79 | 17.8 ± 4.63 | 19.7 ± 5.96 | 53.1 ± 7.80 | 23.2 ± 7.02 | 85.6 ± 14.30 | 138.9 ± 21.11 |
Arm | 25.6 ± 1.98 | 23.7 ± 3.59 | 20.5 ± 2.16 | 21.0 ± 4.40 | 56.4 ± 5.12 | 26.1 ± 3.55 | 90.5± 9.43 | 147.7 ± 13.06 | |
Presence of lymph node metastases | No | 24.5 ± 4.05 | 23.5 ± 5.10 | 18.9 ± 4.12 | 20.0 ± 6.01 | 53.9 ± 7.62 | 24.8 ± 6.60 | 86.7± 14.48 | 140.6 ± 20.90 |
Yes | 24.9 ± 3.49 | 24.3 ± 4.10 | 17.1 ± 5.02 | 19.9 ± 5.81 | 53.4 ± 7.78 | 23.7 ± 6.88 | 86.5 ± 13.39 | 140.7 ± 20.04 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wesslau, H.; Carlander, A.; Ny, L.; Wärnberg, F.; Olofsson Bagge, R.; Lindqvist Bagge, A.-S. Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases. Cancers 2023, 15, 161. https://doi.org/10.3390/cancers15010161
Wesslau H, Carlander A, Ny L, Wärnberg F, Olofsson Bagge R, Lindqvist Bagge A-S. Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases. Cancers. 2023; 15(1):161. https://doi.org/10.3390/cancers15010161
Chicago/Turabian StyleWesslau, Hanna, Anders Carlander, Lars Ny, Fredrik Wärnberg, Roger Olofsson Bagge, and Ann-Sophie Lindqvist Bagge. 2023. "Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases" Cancers 15, no. 1: 161. https://doi.org/10.3390/cancers15010161